H3 Biomedicine Inc. is a unique oncology discovery enterprise guided by the vision of scientific founders and partnered with Eisai, Inc. Headquartered in Cambridge, MA, H3 Biomedicine is integrating human cancer genomics with next-generation synthetic organic chemistry and tumor biology capabilities to generate a large library of novel small-molecule drugs to treat cancer.